帕博利珠单抗联合化疗一线治疗表达PD-L1的转移性三阴性乳腺癌的Q-TWiST分析
基于KEYNOTE-355试验最终分析数据,采用Q-TWiST方法比较帕博利珠单抗联合化疗与单纯化疗在PD-L1阳性(CPS≥10)转移性三阴性乳腺癌患者中的质量调整生存。在中位随访44个月时,联合组Q-TWiST较单纯化疗组增加3.7个月(相对增益18%;P=0.003);在最大随访52个月时增加4.3个月(相对增益20%;P=0.004)。结论认为联合化疗在Q-TWiST方面具有统计学显著且临床重要的改善。
要点
- 帕博利珠单抗联合化疗较单纯化疗在中位随访44个月时Q-TWiST增加3.7个月(相对增益18%;P=0.003)。
- 在最大随访52个月时Q-TWiST增加4.3个月(相对增益20%;P=0.004)。
- Q-TWiST增益随随访时间延长而增加。
核心结论
- 在既往未治疗的PD-L1阳性(CPS≥10)转移性三阴性乳腺癌患者中,帕博利珠单抗联合化疗较单纯化疗在Q-TWiST方面具有统计学显著且临床重要的改善。
研究设计与样本
- 基于KEYNOTE-355试验最终分析数据,采用Q-TWiST分析比较帕博利珠单抗联合化疗与单纯化疗。
- 将患者生存时间划分为三个健康状态:疾病进展前毒性期(TOX)、疾病进展前无症状或毒性期(TWiST)和复发期(REL)。
- 健康状态效用值采用KEYNOTE-355中收集的EQ-5D-3L数据估计,Q-TWiST为各健康状态平均持续时间经效用加权后的总和。
主要发现
- 在中位随访44个月时,帕博利珠单抗联合化疗组较单纯化疗组Q-TWiST增加3.7个月(相对增益18%;P=0.003)。
- 在最大随访52个月时,帕博利珠单抗联合化疗组较单纯化疗组Q-TWiST增加4.3个月(相对增益20%;P=0.004)。
- Q-TWiST增益随随访时间延长而增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the KEYNOTE-355 (KN355) trial, pembrolizumab in combination with chemotherapy demonstrated superior efficacy and manageable safety compared with chemotherapy alone in patients with previously untreated locally recurrent inoperable and metastatic triple-negative breast cancer (mTNBC) with PD-L1 positive (Combined Positive Score [CPS]≥ 10) tumours. This study aimed to evaluate the clinical benefits and risks of pembrolizumab measured by quality-adjusted survival in the trial population. METHODS: The study used data from the final analysis of KN355. The Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) analysis was used to compare treatments of pembrolizumab plus chemotherapy versus chemotherapy alone. Patients' survival time was partitioned into three health states - toxicity before disease progression (TOX), time without symptoms or toxicity before disease progression (TWiST), and relapse (REL). Utilities for these health states were estimated using EuroQol-5 Dimensions, 3 Levels (EQ-5D-3L) data collected in KN355. Q-TWiST was derived as the utility-weighted sum of the mean health state durations. RESULTS: Patients randomised to pembrolizumab plus chemotherapy had 3.7 months greater Q-TWiST (relative gain of 18%; P = 0.003) compared to those randomised to chemotherapy at the median follow-up of 44 months, and 4.3 months greater Q-TWiST (relative gain of 20%; P = 0.004) at the maximum follow-up of 52 months. The Q-TWiST gain increased with longer follow-up time. CONCLUSIONS: Pembrolizumab plus chemotherapy was associated with statistically significant and clinically important improvement in Q-TWiST compared to chemotherapy in previously untreated PD-L1-positive mTNBC.
引用
- Huang M, O'Shaughnessy J, Haiderali A, et al. Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. Eur J Cancer. 2022. PMID: 36323052. doi:10.1016/j.ejca.2022.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。